Long-term efficacy of deferasirox in preventing cardiovascular complications in the iron-overloaded gerbil.

Iron-induced cardiovascular disease is the leading cause of death in iron-overloaded patients. Deferasirox is a novel tridentate oral chelator that exhibits a half-life suitable for once-daily dosing; however, little is known regarding the effectiveness of this agent in preventing iron-induced cardiovascular disease. Adult male Mongolian gerbils were randomly divided into 3 groups: control, iron overload, and iron overload followed by deferasirox treatment.

Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil.

Iron overload is associated with an increased risk of liver complications including fibrosis, cirrhosis, and hepatocellular carcinoma. Deferasirox is a new oral chelator with high iron-binding potency and selectivity. Here we investigate the ability of deferasirox to remove excessive hepatic iron and prevent iron-induced hepatic injury.

Physician attitudes toward collaborative agreements with pharmacists and their expectations of community pharmacists' responsibilities in West Virginia.

Objectives: To (1) investigate physicians' expectations about community pharmacist's roles and physician attitudes toward collaborative agreements with community pharmacists in West Virginia and (2) determine physicians' perceptions of pharmacists providing medication therapy management (MTM) services.

Methods: A mail survey was conducted for a random sample of 500 physicians practicing in West Virginia. Survey items measured the physicians' perceptions about the roles of pharmacists, their level of comfort with pharmacists providing certain MTM services, and their attitudes toward a collaborative agreement with pharmacists.

Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.

Iron-induced cardiovascular disease is the leading cause of death in iron-overloaded patients. Deferasirox is a novel, once daily oral iron chelator that was recently approved for the treatment of transfusional iron overload. Here, we investigate whether deferasirox is capable of removing cardiac iron and improving iron-induced pathogenesis of the heart using the iron overload gerbil model.